EP2663306A4 - Polymorphe aus dexlansoprazolsalzen - Google Patents

Polymorphe aus dexlansoprazolsalzen

Info

Publication number: EP2663306A4
Authority: EP; European Patent Office
Prior art keywords: dexlansoprazole; polymorphs; salts; dexlansoprazole salts
Prior art date: 2011-01-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP11855797.4A

Other languages

English (en)

French (fr)

Other versions

EP2663306A1 (de

Inventor

Reddy Bandi Parthasaradhi

Reddy Kura Rathnakar

Reddy Dasari Muralidhara

Reddy Matta Ramakrishna

Krishna Bandi Vamsi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hetero Research Foundation

Original Assignee

Hetero Research Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-12

Filing date

2011-11-11

Publication date

2014-01-01

2011-11-11 Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation

2013-11-20 Publication of EP2663306A1 publication Critical patent/EP2663306A1/de

2014-01-01 Publication of EP2663306A4 publication Critical patent/EP2663306A4/de

Status Withdrawn legal-status Critical Current

Links

MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical class CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP11855797.4A 2011-01-12 2011-11-11 Polymorphe aus dexlansoprazolsalzen Withdrawn EP2663306A4 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN102CH2011		2011-01-12
PCT/IN2011/000782 WO2012095859A1 (en)	2011-01-12	2011-11-11	Polymorphs of dexlansoprazole salts

Publications (2)

Publication Number	Publication Date
EP2663306A1 EP2663306A1 (de)	2013-11-20
EP2663306A4 true EP2663306A4 (de)	2014-01-01

Family

ID=46506821

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11855797.4A Withdrawn EP2663306A4 (de)	2011-01-12	2011-11-11	Polymorphe aus dexlansoprazolsalzen

Country Status (2)

Country	Link
EP (1)	EP2663306A4 (de)
WO (1)	WO2012095859A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103788068B (zh) *	2014-02-26	2016-04-06	南京海融医药科技有限公司	高熔点的手性苯并咪唑类化合物钠盐、制备方法及其用途
CN106727381B (zh) *	2016-12-29	2020-07-07	南京海融制药有限公司	一种右兰索拉唑钠的口崩片及其制备方法
CN106668018B (zh) *	2016-12-29	2019-12-06	南京海融制药有限公司	一种右兰索拉唑钠的缓释胶囊及其制备方法
CN106749186B (zh) *	2016-12-29	2019-03-05	南京海融制药有限公司	一种右兰索拉唑钠的新晶型及其制备方法
CN106619520B (zh) *	2016-12-29	2019-08-06	南京海融制药有限公司	一种右兰索拉唑钠的干混悬剂及其制备方法
CN109836413A (zh) *	2017-11-27	2019-06-04	银谷制药有限责任公司	一种右旋兰索拉唑钠晶型及其制备方法和用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000078729A1 (en) *	1999-06-18	2000-12-28	Instytut Farmaceutyczny	Crystalline forms of lansoprazole
WO2003082857A2 (en) *	2002-03-27	2003-10-09	Teva Pharmaceutical Industries Ltd.	Lansoprazole polymorphs and processes for preparation thereof
WO2004083200A1 (en) *	1999-06-17	2004-09-30	Akira Fujishima	Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
EP1889841A1 (de) *	2005-06-07	2008-02-20	Takeda Pharmaceutical Company Limited	Kristall eines salzes einer benzimidazolverbindung
WO2009087672A1 (en) *	2007-12-18	2009-07-16	Watson Pharma Private Limited	A process for preparation of stable amorphous r-lansoprazole
WO2010039885A2 (en) *	2008-09-30	2010-04-08	Teva Pharmaceutical Industries Ltd.	Crystalline forms of dexlansoprazole
WO2010056059A2 (en) *	2008-11-14	2010-05-20	Hanmi Pharm. Co., Ltd.	Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
EP2216333A2 (de) *	2009-02-06	2010-08-11	Dipharma Francis S.r.l.	Kristalline Formen von Dexlansoprazol
WO2011121546A1 (en) *	2010-03-31	2011-10-06	Ranbaxy Laboratories Limited	Salts of dexlansoprazole and their preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4104470A (en) *	1977-06-03	1978-08-01	Eli Lilly And Company	Crystallization process for cefazolin sodium
JP5412023B2 (ja) *	2000-08-04	2014-02-12	武田薬品工業株式会社	ベンズイミダゾール化合物の塩およびその用途
CA2510849A1 (en) *	2002-12-19	2004-07-08	Teva Pharmaceutical Industries Ltd	Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
EP1827429A4 (de) *	2004-12-20	2009-08-05	Reddys Lab Ltd Dr	Pharmatzeutische zusammensetzungen mit amorphen benzimidazolverbindungen
WO2007122686A1 (ja) *	2006-04-14	2007-11-01	Eisai R & D Management Co., Ltd.	ベンズイミダゾール化合物
WO2009117489A1 (en) *	2008-03-18	2009-09-24	Dr. Reddy's Laboratories Ltd.	Dexlansoprazole process and polymorphs

2011
- 2011-11-11 WO PCT/IN2011/000782 patent/WO2012095859A1/en not_active Ceased
- 2011-11-11 EP EP11855797.4A patent/EP2663306A4/de not_active Withdrawn

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004083200A1 (en) *	1999-06-17	2004-09-30	Akira Fujishima	Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
WO2000078729A1 (en) *	1999-06-18	2000-12-28	Instytut Farmaceutyczny	Crystalline forms of lansoprazole
WO2003082857A2 (en) *	2002-03-27	2003-10-09	Teva Pharmaceutical Industries Ltd.	Lansoprazole polymorphs and processes for preparation thereof
EP1889841A1 (de) *	2005-06-07	2008-02-20	Takeda Pharmaceutical Company Limited	Kristall eines salzes einer benzimidazolverbindung
WO2009087672A1 (en) *	2007-12-18	2009-07-16	Watson Pharma Private Limited	A process for preparation of stable amorphous r-lansoprazole
WO2010039885A2 (en) *	2008-09-30	2010-04-08	Teva Pharmaceutical Industries Ltd.	Crystalline forms of dexlansoprazole
WO2010056059A2 (en) *	2008-11-14	2010-05-20	Hanmi Pharm. Co., Ltd.	Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
EP2216333A2 (de) *	2009-02-06	2010-08-11	Dipharma Francis S.r.l.	Kristalline Formen von Dexlansoprazol
WO2011121546A1 (en) *	2010-03-31	2011-10-06	Ranbaxy Laboratories Limited	Salts of dexlansoprazole and their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012095859A1 *

Also Published As

Publication number	Publication date
WO2012095859A1 (en)	2012-07-19
EP2663306A1 (de)	2013-11-20

Legal Events

Date	Code	Title	Description
2013-10-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-11-20	17P	Request for examination filed	Effective date: 20130724
2013-11-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-01-01	A4	Supplementary search report drawn up and despatched	Effective date: 20131129
2014-01-01	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/4439 20060101ALI20131125BHEP Ipc: C07D 401/12 20060101AFI20131125BHEP
2014-04-16	DAX	Request for extension of the european patent (deleted)
2014-12-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2015-01-14	18D	Application deemed to be withdrawn	Effective date: 20140603

Publication	Publication Date	Title
CO6960542A2 (es)	2014-05-30	Polimorfos de inhibidores de cinasas
IL232599A (en)	2017-03-30	Hydrobromide salt of peridofidine
SI2707368T1 (sl)	2016-04-29	Polimorf linagliptin benzoata
ZA201402492B (en)	2015-07-29	Polymorphic form of pridopidine hydrochloride
EP2709609A4 (de)	2015-08-26	Heterozyklische verbindungen
GB201304499D0 (en)	2013-04-24	Carcainium Salts
IL230976A0 (en)	2014-03-31	Crystalline forms of cvezitaxel
EP2776428A4 (de)	2015-04-22	Kinasehemmerpolymorphe
EP2776393A4 (de)	2015-05-27	Nampt-inhibitoren
EP2760853A4 (de)	2015-10-28	Neuartige salze aus alogliptin
EP2758387A4 (de)	2015-03-11	Pyridinverbindungen als kinase-inhibitoren
PL3287131T3 (pl)	2020-10-19	Terapeutyczne zastosowania ektoiny
SG11201400452TA (en)	2014-08-28	Derivatives of xanthone compounds
EP2800747A4 (de)	2015-12-09	Polymorphe von perampanel
ZA201308160B (en)	2015-01-28	Crystalline salts of asenapine
PT2751081T (pt)	2017-04-04	Forma polimórfica de pitavastatina cálcica
GB201120644D0 (en)	2012-01-11	Herbicidal uses of compounds
EP2663306A4 (de)	2014-01-01	Polymorphe aus dexlansoprazolsalzen
EP2744788A4 (de)	2015-04-15	Benzopiperazinderivate als cetp-hemmer
EP2680843A4 (de)	2015-05-06	Derivate von pyrazolsubstituierten amino-heteroaryl-verbindungen
EP2684869A4 (de)	2014-08-20	Herstellung von 3-mercaptopropionaten
IL230977A (en)	2016-08-31	A crystalline form of relapaldib
ZA201401492B (en)	2016-10-26	Method for ease of ironing
EP2782902A4 (de)	2015-08-26	Derivate aus phenoxyisobuttersäure
SI2729461T1 (sl)	2016-06-30	Polimorfi 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida